Richard Bergstrom

The European Medicines Verification Organisation “The European Medicines Verification Organisation (EMVO) is the guarantee of patient security in Europe.” The European Medicines Verification Organisation (EMVO) has taken responsibility for advancing the formation of the European Medicines Verification System (EMVS). The EMVS is in accordance with the EU’s Falsified Medicines Directive (FMD) and the Delegated Regulation (DR). It ensures the implementation of a functioning, secure, interoperable and cost effective system across Europe. The infiltration of falsified medicines in the European supply chain is a major and continuous threat for the patient health and security. Because patient health and safety is of the utmost importance to the pharmaceutical industry, a comprehensive strategy at European Level is required. Therefore the European Medicines Verification Organisation (EMVO) was created as a joint initiative of EU stakeholders, representing manufacturers (Medicines for Europe, EFPIA, Affordable Medicines Europe), wholesalers (GIRP) and community pharmacists (PGEU). Twitter: @emvo_official Website: www.emvo-medicines.eu

The Innovative Health Initiative (IHI) aims to translate health research and innovation into real benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involve diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to health care, covering prevention, diagnosis, treatment, and disease management. IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical technology, biotechnology, digital health and vaccine industries, namely COCIR, EFPIA (including Vaccines Europe), EuropaBio, and MedTech Europe. IHI’s total budget is EUR 2.4 billion. Half of this comes from Horizon Europe, the EU’s research and innovation programme. The IHI industry partners have committed EUR 1 billion to IHI, and a further EUR 200 million can be committed by other organisations that decide to become Contributing Partners. IHI builds on the successes of the Innovative Medicines Initiative (IMI), which ran from 2008 to 2021. The IHI Programme Office continues to manage and promote projects launched under IMI. Follow us on Twitter at @IHIEurope

The Institute of Health Economics (IHE) is an independent, not-for-profit organization with key competencies in health economics and decision analytic modelling, health technology assessment, and knowledge transfer/exchange. Our mission is to inform coordinated, innovative, evidence-guided health policy and practice. The Institute has broad linkages within academic, private, and public sectors, on provincial, national, and international levels that permits significant capacity and access to expertise, and amplifies the contribution of the organization via network dissemination of evidence and information. The IHE serves as: - the provincial program for health technology assessment in Alberta; - the secretariat for the Network of Alberta Health Economists (NOAHE) (www.NOAHE.ca); and to the Alberta Real World Evidence Consortium (www.AlbertaRWE.ca) - a member of and host agency/secretariat for the International Network of Agencies for Health Technology A- assessment (INAHTA) (www.inahta.org); - a member of and host agency/secretariat for Health Technology Assessment International (HTAi) (www.HTAi.org); - a technical member of the World Health Organization's Health Evidence Network (WHO HEN); and - a member of the Canadian Agency for Drugs and Technologies in Health (CADTH) Health Technology Analysis Exchange and Pan-Canadian HTA Collaborative. To learn more about the IHE, visit us at www.IHE.ca!

CCX empowers you to plan, negotiate, and administer deals on your terms, with a simple and configurable infrastructure. Our proven technology delivers your strategy, and better outcomes.

A good navigation tool is essential when flying, sailing or driving. The benefit is enormous: you get to your goal quicker and more safely. The advisory team at Hölzle, Buri & Partner Consulting (HBPC) sees itself as your companion in finding and achieving your goals. In a world where market requirements change quickly, an external consultation process where management is fully integrated into the strategy-finding process is invaluable. We modernise processes and poses critical questions in our role as independent consultants. RECRUITMENT We offer the following additional benefits: Everyone goes through a system-supported assessment process. All partners have many years of international management and recruitment experience and are therefore able to examine proof of performance very closely. Given our market knowledge, we can check the information provided by candidates very closely

The European Medicines Verification Organisation “The European Medicines Verification Organisation (EMVO) is the guarantee of patient security in Europe.” The European Medicines Verification Organisation (EMVO) has taken responsibility for advancing the formation of the European Medicines Verification System (EMVS). The EMVS is in accordance with the EU’s Falsified Medicines Directive (FMD) and the Delegated Regulation (DR). It ensures the implementation of a functioning, secure, interoperable and cost effective system across Europe. The infiltration of falsified medicines in the European supply chain is a major and continuous threat for the patient health and security. Because patient health and safety is of the utmost importance to the pharmaceutical industry, a comprehensive strategy at European Level is required. Therefore the European Medicines Verification Organisation (EMVO) was created as a joint initiative of EU stakeholders, representing manufacturers (Medicines for Europe, EFPIA, Affordable Medicines Europe), wholesalers (GIRP) and community pharmacists (PGEU). Twitter: @emvo_official Website: www.emvo-medicines.eu

The EUROPEAN HEALTH FORUM GASTEIN (EHFG) is a European health policy conference with the aim of providing a platform for discussion for the various stakeholders in the field of public health and health care. The EHFG has developed into a unique annual event, bringing together, politicians, senior decision-makers, representatives of interest groups, as well as experts coming from government and administration, business and industry, civil society and science and academia.